Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest amyloidosis Stories

2014-04-07 12:32:53

SAN DIEGO, April 7, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a preclinical-stage RNA medicines company pursuing rare diseases, today announced its President & CEO, Joseph E. Payne, has been invited to present at the 13(th) Annual Needham Healthcare Conference 2014, being held April 8-9 at The Westin Grand Central Hotel in New York City. In addition to a corporate summary, Payne's presentation will provide new data on the targeted delivery of RNA to the liver and kidney,...

2014-03-27 08:33:06

- LUNAR TM technology for the delivery of RNA medicines to multiple target organs and tumors will be presented SAN DIEGO, March 27, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a next wave RNA medicines company pursuing orphan diseases, today announced that its president & CEO, Joseph E. Payne, has been invited to present at the 21(st) Annual BioCentury Future Leaders in the Biotech Industry Conference, being held on March 28, 2014. In addition to providing a corporate...

2014-03-14 23:23:04

Professional Baseball Players to Gather in Scottsdale, AZ to Raise Awareness for Amyloidosis Scottsdale, Arizona (PRWEB) March 14, 2014 Baseball Prospectus, owner of BaseballProspectus.com, Issues Concerning Athletes, a real estate venture which targets professional athletes, and MiCamp Merchant Services announced today that it will host the fourth annual “Celebrity Bartending Night,” on Saturday, March 22 at American Junkie to benefit Amyloidosis Support Groups. Amyloidosis is a...

2014-03-10 08:28:30

- In Vivo Delivery of RNA Medicines to Multiple Tissues Utilizing its Proprietary LUNARTM Delivery Technology - SAN DIEGO, March 10, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing orphan diseases, today announced that it has been selected to present at BIO-Europe Spring Partnering Conference 2014, being held March 10-12 in Turin, Italy. In addition to providing an update on Arcturus' flagship program targeting transthyretin (TTR)-mediated...

2014-02-14 16:24:52

CARLSBAD, Calif., Feb. 14, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending ISIS-TTR(Rx) for designation as an orphan medicinal product for the treatment of ATTR-Amyloidosis to the European Commission (EC). The opinion will be subject to review by the EC, which ultimately grants the decision on orphan drug designation. ATTR-Amyloidosis, or TTR amyloidosis,...

2014-01-13 04:21:08

New Preclinical Results in Non-Human Primates Demonstrate Significant and Sustained Reduction of Transthyretin Using its Proprietary LUNARTM Delivery Technology SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., an industry leader in RNA technologies, today announced its flagship program - an RNAi therapeutic targeting transthyretin (TTR)-mediated amyloidosis. Preclinical non-human primate data will be presented at the Biotech Showcase being held January 13, 2014...

2013-11-07 23:34:09

Solex LLC. (http://www.solex-biomedical.com) has licensed a peptide-based technology for the diagnostic visualization of amyloid burden in patients with amyloid-related diseases by using molecular imaging techniques. This 31 amino acid, synthetic peptide p5 can be easily produced for human use, and can be used in most hospitals world wide for the detection of Amyloidosis. Knoxville, Tennessee (PRWEB) November 07, 2013 Solex LLC. has licensed a peptide-based technology for the diagnostic...

2013-10-21 08:29:34

DALLAS, Oct. 21, 2013 /PRNewswire/ -- For those who suffer from an irregular heartbeat known as atrial fibrillation, getting in rhythm and staying in rhythm is a goal. At the Get in Rhythm, Stay in Rhythm Atrial Fibrillation Patient Conference to be held in Dallas on November 2, 2013, medical experts will help patients, their families, and caregivers learn more about this condition that affects millions of Americans. What: Get in Rhythm, Stay in Rhythm Atrial Fibrillation Patient Conference...

2013-09-25 08:29:53

DALLAS, Sept. 25, 2013 /PRNewswire/ -- September 2013 is the seventh annual Atrial Fibrillation Awareness Month. As one of the world's leading atrial fibrillation (AF or afib) awareness-raising organizations, StopAfib.org has shared a wealth of information about this potentially life-threatening disease. Afib, the most common irregular heartbeat, can lead to dementia, heart failure, stroke, or even death. Many do not realize that they have it, and many who have it don't realize...

2013-09-11 08:28:35

DALLAS, Sept. 11, 2013 /PRNewswire/ -- Atrial fibrillation (also called afib or AF) is an irregular heartbeat (or heart rhythm) and is a much more serious condition than many patients - and their family members - realize. Many patients don't know about the risk of stroke, according to StopAfib.org, a leading global atrial fibrillation patient organization. Having afib increases your stroke risk by 500 percent. Of those who have afib, 1 out of 3 will have a stroke in their lifetime....